Interstitial brachytherapy with permanent seed implants in early prostate cancer.
Excellent clinical results after permanent seed implantation have been reported by various centers in large cohorts of patients. However, all of these had extensive experience in this special field of radiotherapy and the therepy and the follow-up time is too short for definite conclusions. The fact that this option of treatment can be carried out on an outpatient basis and that it allows to get the patient back to normal as far as social environment and work are concerned, has led to wide acceptance of this particular mode of therapy. Therefore, permanent seed implantation is a possible treatment option for localized prostate cancer and can be  offered to patients with T1- T2a  tumors, PSA levels of < 10 and a Gleason score of < 7. By using permanent seed implantation in these selected patients, it seems possible to achieve results comparable with surgery alone or  percutaneous, 3D-planned radiotherapy.
Maurer
U
U
Kliniken für Strahlentherapie, Universitätsklinikum der RWTH, Aachen, Deutschland.
Wiegel
Th
T
Hinkelbein
W
W
Eble
M J
MJ
D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy*; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D001918:Brachytherapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D018572:Disease-Free Survival; D004343:Drug Implants; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004343:Drug Implants; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D017430:Prostate-Specific Antigen